Increasing gaps and decreasing returns attenuate spending effects. by William Minozzi (8564712)

Detailed treatment status of people who received non- pharmacological treatment at first diagnosis. by Mingee Choi (15250732)

Subjects:

Regenerating axons are increased by ATRA and decreased by clodronate. by Valeria De La Rosa-Reyes (6658613)

“…Compared to PBS-treated, the number of regenerating axons is doubled by ATRA treatment, decreased by 30% by clodronate, and, in the case of ATRA combined with clodronate, is not significantly different.…”

Treatment at first diagnosis of insomnia disorder (%). by Mingee Choi (15250732)

Subjects:

Detailed treatment status of patients who did not receive non-pharmacological treatment at first diagnosis but received it later. by Mingee Choi (15250732)

Subjects:

Anthelmintic treatment significantly increased the plasma cytokine levels in T2DM. by Anuradha Rajamanickam (5278013)

Anthelmintic treatment significantly increased the plasma chemokine levels in T2DM. by Anuradha Rajamanickam (5278013)

ABA treatment does not significantly increase LsNCED4 expression. by James Eckhardt (20416848)

Distribution of non-pharmacological treatment related to insomnia disorder (2002–2019). by Mingee Choi (15250732)

Subjects:

Mean interval from initial diagnosis to initiation of non-pharmacological treatment by year. by Mingee Choi (15250732)

Subjects:

Treatment with rhMG53 significantly increases regeneration past the crush site. by Brian J. Paleo (8694246)

“…B, C) Treatment with rhMG53 increased the regeneration index. …”

Annual incidence of insomnia disorder (ICD-CODE: G47) Bar: rate of insomnia disorder relative to all patients; Line: average number of outpatient visits for patients with insomnia... by Mingee Choi (15250732)

Subjects:

General information of patient who diagnosis insomnia disorder (N = 518,119). by Mingee Choi (15250732)

Subjects:

Laser irradiation in the PBMT group. by Katayoon Montazeri (18389243)

Subjects:

Between-groups comparison of GIN and PPI values in control, tinnitus and PBMT groups. by Katayoon Montazeri (18389243)

Subjects:

Mean±SD of BTT and threshold in control, tinnitus and PBMT groups. by Katayoon Montazeri (18389243)

Subjects:

Diagram of methods. by Katayoon Montazeri (18389243)

Subjects:

Doublecortin (DCX) expression in 3 brain regions (coronal sections) in the control (Cont), Tinnitus (TIN) and PBMT (PBMT) groups. by Katayoon Montazeri (18389243)

Subjects:

PBMT parameters. by Katayoon Montazeri (18389243)

Subjects:

Fig 4 - by Katayoon Montazeri (18389243)

Subjects: